Sociodemographic characteristics of the study population
| Characteristics of the study population | Total (n=492) n (%); mean+SD; median (IQR) |
|---|---|
| Age | 71.77±5.954; 70.0; (6.0) |
| Sex (female) | 306 (62.2%); 186; (37.8) |
| Total number of prescribed medications | 4.37±2.234; 4.0; (3.0) |
| Most common diagnoses | |
| arterial hypertension | 254 (51.6%); 238; (48.4) |
| cardiac insufficiency | 218 (44.3%); 274; (55.7) |
| depression | 106 (21.5%); 386; (78.5) |
| type 1 diabetes mellitus | 80 (16.3%); 412; (83.7) |
| benign prostatic hyperplasia | 70 (14.2%); 422; (85.8) |
| asthma | 26 (5.3%); 466; (94.7) |
| epilepsy | 18 (3.7%); 474; (96.3) |
Risk factors associated with potentially inappropriate prescribing of psychotropic drugs according to STOPP/START criteria
| STOPP criteria | Raw OR 95% (CI) | Adjusted OR 95% (CI) | ||
|---|---|---|---|---|
| Risk factors | ||||
| Arterial hypertension | 2.451 (1.705–3.522) | 0.000 | 0.419 (0.141–1.245) | 0.118 |
| Cardiac insufficiency | 0.604 (0.422–0.864) | 0.006 | 1.296 (0.470–3.575) | 0.617 |
| Asthma | 2.431 (1.036–5.701) | 0.041 | 1.329 (0.231–7.644) | 0.750 |
| Depression | 93.449 (22.711–384.515) | 0.000 | 18.138 (3.367–97.704) | 0.001 |
| Number of diseases | 2.332 (1.858–2.927) | 0.000 | 3.805 (1.911–7.578) | 0.001 |
| Total number of drugs | 1.391 (1.265–1.530) | 0.000 | 1.031 (0.812–1.310) | 0.801 |
| Problems with the use of psychotropic drugs | 24.554 (5.863–102.834) | 0.000 | 43.517 (5.453–347.267) | 0.001 |
| Number of OTC sales | 2.029 (1.536–2.680) | 0.000 | 1.625 (0.892–2.959) | 0.113 |
| Number of dietary supplements | 1.538 (1.218–1.942) | 0.002 | 1.262 (0.689–2.309) | 0.451 |
| Use of antidepressants | 84.389 (20.501–347.370) | 0.000 | 52.810 (6.217–448.561) | 0.000 |
|
|
|
|
|
| Number of patient examinations in the last 12 months | 1.388 (1.255–1.535) | 0.000 | 1.307 (1.005–1.699) | 0.046 |
| Number of hospitalizations in the last 12 months | 1.540 (1.248–1.900) | 0.000 | 1.089 (0.736–1.612) | 0.669 |
| Number of performed diagnostic procedures | 1.233 (1.111–1.369) | 0.000 | 1.196 (0.930–1.539) | 0.163 |
| Years of service of the eGP | 1.138 (1.104–1.173) | 0.000 | 1.017 (0.926–1.116) | 0.728 |
| Number of patients of the sGP | 1.004 (1.003–1.006) | 0.000 | 1.003 (1.000–1.005) | 0.027 |
| Number of adverse reactions to psychotropic drugs | 6.411 (2.222–18.500) | 0.001 | 0.572 (0.029–11.313) | 0.714 |
| Age | 1.031 (1.001–1.063) | 0.045 | 0.920 (0.861–0.982) | 0.012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk factors associated with potential failure to prescribe psychotropic drugs according to STOPP / START criteria
| START criteria | Raw OR 95% (CI) | Adjusted OR 95% (CI) | ||
|---|---|---|---|---|
| Risk factors | ||||
| Arrhythmia | 0.478 (0.303–0.752) | 0.001 | 0.756 (0.331–1.724) | 0.505 |
| COPD | 0.242 (0.075–0.782) | 0.018 | 0.033 (0.005–0.207) | 0.001 |
| Depression | 3.929 (2.278–6.779) | 0.000 | 1.507 (0.499–4.552) | 0.467 |
| Number of diseases | 1.277 (1.060–1.537) | 0.010 | 1.198 (0.787–1.826) | 0.400 |
| Total number of drugs | 1.227 (1.120–1.344) | 0.000 | 1.458 (1.172–1.815) | 0.001 |
| Number of OTC sales | 1.757 (1.321–2.338) | 0.000 | 1.514 (0.943–2.433) | 0.086 |
| Number of dietary supplements | 1.445 (1.136–1.838) | 0.003 | 1.328 (0.867–2.036) | 0.192 |
| Antipsychotics | 1.866 (1.167–2.982) | 0.009 | 4.049 (1.730–9.476) | 0.001 |
| Anxiolytics | 0.578 (0.349–0.849) | 0.005 | 0.303 (0.140–0.657) | 0.002 |
|
|
|
|
|
| Number of patient examinations in the last 12 months | 1.110 (1.016–1.214) | 0.021 | 0.968 (0.766–1.225) | 0.788 |
| Number of hospitalizations in the last 12 months | 1.355 (1.090–1.685) | 0.006 | 1.104 (0.820–1.486) | 0.514 |
| Number of performed diagnostic procedures | 1.174 (1.056–1.305) | 0.003 | 1.262 (1.036–1.537) | 0.021 |
|
| 0.000 | 0.953 (0.205–4.440) | 0.952 |
| Number of patients of the sGP | 1.003 (1.002–1.004) | 0.000 | 1.002 (1.000–1.004) | 0.091 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|